Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers
Advertisement

Related Content

India’s Expanding Vaccines Market Offers Promise To Global And Local Drug Firms (Part 2 of 2)
WHO Nod To India’s Regulatory System A Booster For Vaccine Makers
India’s Vaccine Giant Serum Institute Sees Yearly Sales At $500 Million Until 2015 From Global Alliance Effort
Serum Institute Of India Chairman Cyrus Poonawalla On How To Succeed In The Vaccines Business: An Interview With PharmAsia News
India’s Vaccine Giant Serum Institute Sees Yearly Sales At $500 Million Until 2015 From Global Alliance Effort
R&D Funding, Epidemiology And Balanced Policies To Fuel India Growth - CII Lifescience Conclave
R&D Funding, Epidemiology And Balanced Policies To Fuel India Growth - CII Lifescience Conclave
Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
Advertisement
UsernamePublicRestriction

Register

SC078778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel